Latest Payments News

Aeeris Ltd reported a 27.7% revenue increase to $4.36 million for FY25, driven by proprietary platform launches and expanded client contracts, while posting a net loss of $632,731. The company is poised for operational scale and cash flow positivity in FY26.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

333D Limited has reported a remarkable turnaround for the year ended June 2025, posting a profit after tax of $143,777 on the back of a 426% revenue increase driven by its digital asset management strategy. The company also adopted a Bitcoin Treasury Management Policy, signaling a new phase in its financial approach.

Humm Group Limited has announced a fully franked ordinary dividend of AUD 0.0075 per share for the six months ending June 2025, alongside a Dividend Reinvestment Plan offering.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Salter Brothers Emerging Companies Limited posted a 25.5% decline in profit after tax for FY25 but marked a milestone with its inaugural dividend payment. The fund remains confident in its small-cap investment strategy amid easing interest rates and geopolitical volatility.

Transmetro Corporation Limited reported robust financial results for FY25, with revenue and profit significantly up, underpinning a steady dividend payout.

Airtasker Limited reported a 12.8% increase in revenue to $52.6 million for FY25, driven by growth in Australia, the UK, and the US. However, the company’s net loss widened significantly to $37.7 million, reflecting heavy investment in global marketing and media partnerships.